Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lynette Keyes-Elstein

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
The Lancet. Rheumatology|February 1, 2024
Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trialEliza F Chakravarty, Tammy Utset, Diane L Kamen, et al.
The Lancet. Diabetes & Endocrinology|March 14, 2014
Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trialMark R Rigby, Linda A DiMeglio, Marc S Rendell, et al.
Rheumatology (Oxford, England)|September 10, 2019
Unique Sjögren's syndrome patient subsets defined by molecular featuresJudith A James, Joel M Guthridge, Hua Chen, et al.
The Journal of Rheumatology|February 19, 2013
Gastric antral vascular ectasia and its clinical correlates in patients with early diffuse systemic sclerosis in the SCOT trialEmily W Hung, Maureen D Mayes, Roozbeh Sharif, et al.
The Journal of Clinical Investigation|July 21, 2015
Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patientsMark R Rigby, Kristina M Harris, Ashley Pinckney, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 30, 2025
A phase 2 trial of hydroxychloroquine in individuals at risk for rheumatoid arthritisKevin D Deane, Christopher C Striebich, Marie L Feser, et al.
JCI Insight|November 8, 2021
IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetesCarla J Greenbaum, Elisavet Serti, Katharina Lambert, et al.
The New England Journal of Medicine|January 4, 2018
Myeloablative Autologous Stem-Cell Transplantation for Severe SclerodermaKeith M Sullivan, Ellen A Goldmuntz, Lynette Keyes-Elstein, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
The Lancet. Rheumatology|February 1, 2024
Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trialEliza F Chakravarty, Tammy Utset, Diane L Kamen, et al.
The Lancet. Diabetes & Endocrinology|March 14, 2014
Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trialMark R Rigby, Linda A DiMeglio, Marc S Rendell, et al.
Rheumatology (Oxford, England)|September 10, 2019
Unique Sjögren's syndrome patient subsets defined by molecular featuresJudith A James, Joel M Guthridge, Hua Chen, et al.
The Journal of Rheumatology|February 19, 2013
Gastric antral vascular ectasia and its clinical correlates in patients with early diffuse systemic sclerosis in the SCOT trialEmily W Hung, Maureen D Mayes, Roozbeh Sharif, et al.
The Journal of Clinical Investigation|July 21, 2015
Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patientsMark R Rigby, Kristina M Harris, Ashley Pinckney, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 30, 2025
A phase 2 trial of hydroxychloroquine in individuals at risk for rheumatoid arthritisKevin D Deane, Christopher C Striebich, Marie L Feser, et al.
JCI Insight|November 8, 2021
IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetesCarla J Greenbaum, Elisavet Serti, Katharina Lambert, et al.
The New England Journal of Medicine|January 4, 2018
Myeloablative Autologous Stem-Cell Transplantation for Severe SclerodermaKeith M Sullivan, Ellen A Goldmuntz, Lynette Keyes-Elstein, et al.
Pageof 3